stoxline Quote Chart Rank Option Currency Glossary
  
Fate Therapeutics, Inc. (FATE)
1.715  0.185 (12.09%)    02-19 15:53
Open: 1.51
High: 1.81
Volume: 5,354,499
  
Pre. Close: 1.53
Low: 1.43
Market Cap: 195(M)
Technical analysis
2025-02-19 3:21:29 PM
Short term     
Mid term     
Targets 6-month :  2.11 1-year :  2.46
Resists First :  1.8 Second :  2.11
Pivot price 1.35
Supports First :  1.41 Second :  1.16
MAs MA(5) :  1.43 MA(20) :  1.34
MA(100) :  2.18 MA(250) :  3.69
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  70.8 D(3) :  54.2
RSI RSI(14): 64.5
52-week High :  8.82 Low :  1.03
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FATE ] has closed above the upper band by 20.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.7 - 1.71 1.71 - 1.71
Low: 1.47 - 1.48 1.48 - 1.49
Close: 1.52 - 1.53 1.53 - 1.54
Company Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Headline News

Mon, 17 Feb 2025
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance

Mon, 17 Feb 2025
Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat

Sun, 16 Feb 2025
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - ACCESS Newswire

Sat, 15 Feb 2025
Research Analysts Offer Predictions for FATE Q1 Earnings - MarketBeat

Fri, 14 Feb 2025
Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Tue, 04 Feb 2025
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 114 (M)
Held by Insiders 9.921e+007 (%)
Held by Institutions 2.2 (%)
Shares Short 11,200 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.6467e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 703.8 %
Return on Equity (ttm) -22.2 %
Qtrly Rev. Growth 1.345e+007 %
Gross Profit (p.s.) 28.76
Sales Per Share -23.07
EBITDA (p.s.) -5.38911e+007
Qtrly Earnings Growth -1.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -132 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.08
Price to Cash Flow 1.08
Stock Dividends
Dividend 0
Forward Dividend 1.287e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android